We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ITT:NYSEITT Inc. Analysis

Data as of 2026-04-11 - not real-time

$216.90

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

ITT Inc. is trading at $216.9, just shy of its 52‑week high of $218.99, with the 20‑day SMA ($192.88) well below price and a bullish MACD histogram (+3.43) indicating upward momentum. However, the RSI of 71 places the stock in overbought territory and the 30‑day volatility of nearly 40% combined with a beta of 1.22 signal heightened short‑term price swings. Fundamentals remain robust: revenue grew 13.5% YoY to $3.94 bn, EPS jumped to $6.12 with forward EPS projected at $8.87, and free cash flow exceeds $444 m, supporting a low payout ratio (~23%). The recent $4.78 bn cash‑and‑stock acquisition of SPX FLOW adds a strategic industrial process platform, expanding global exposure and reinforcing long‑term growth prospects.
Valuation metrics show a forward PE of 24.4 versus an industry average of 30.9, yet the DCF fair value ($127.85) is well below the current price, flagging potential overvaluation. The dividend yield of 0.71% appears sustainable given strong cash balances and modest leverage (debt‑to‑equity 21%). Overall, the stock presents a blend of growth momentum and valuation caution, with the acquisition likely to drive earnings expansion over the medium horizon.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • RSI in overbought zone suggests limited upside
  • Bullish MACD but price near resistance
  • High short‑term volatility

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Revenue growth of 13.5% and EPS acceleration
  • Strategic SPX FLOW acquisition expanding addressable market
  • Target median price of $234 indicating ~8% upside

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Sustainable dividend with low payout ratio
  • Strong free cash flow and modest leverage
  • Diversified global footprint reducing concentration risk

Key Metrics & Analysis

Financial Health

Revenue Growth13.50%
Profit Margin12.39%
P/E Ratio35.4
ROE14.29%
ROA8.13%
Debt/Equity21.20
P/B Ratio4.6
Op. Cash Flow$668.3M
Free Cash Flow$445.0M
Industry P/E30.9

Technical Analysis

TrendNeutral
RSI71.3
Support$180.10
Resistance$218.99
MA 20$192.88
MA 50$195.20
MA 200$179.30
MACDBullish
VolumeIncreasing
Fear & Greed Index87.09

Valuation

Fair Value$127.85
Target Price$233.92
Upside/Downside7.85%
GradeOvervalued
TypeGrowth
Dividend Yield0.71%

Risk Assessment

Beta1.22
Volatility39.79%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.